<DOC>
	<DOCNO>NCT01978548</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics JNJ-54861911 patient prodromal Alzheimer 's disease ( pAD ) .</brief_summary>
	<brief_title>A Study Evaluate Effects JNJ-54861911 Amyloid Beta Processing Cerebrospinal Fluid Plasma Patients With Prodromal Alzheimer 's Disease</brief_title>
	<detailed_description>This multicenter , double-blind ( neither investigator patient know treatment patient receives ) , placebo-controlled ( placebo inactive substance compare drug test whether drug real effect clinical trial ) , randomize ( patient assign different treatment base chance ) , multiple-dose , proof-of-mechanism ( POM ) study pAD . Approximately 24 outpatient ( n=8/treatment group ) diagnose pAD , accord inclusion exclusion criterion , participate 4-week treatment study . For enrolled patient , study consist 8-week eligibility screen period , 4-week double-blind treatment period , follow-up examination ( 7-14 day last dose ) . Patients assign randomly 1 3 treatment group : placebo , JNJ-54861911 10 mg daily , JNJ-54861911 50 mg daily . Safety assessment perform throughout study . The maximal study duration patient 14 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients must sufficient education work experience exclude mental retardation Patients must abnormal cognitive performance consistent mild cognitive impairment base computerized neuropsychological test battery ( CANTAB Elect ) effectively screen patient identify cognitive deficit consistent mild cognitive impairment Patients must evidence amyloid deposition mean either 1 ) low cerebrospinal fluid amyloid beta 142 ( CSF amyloid beta 142 ) level elevate CSF pTau and/or total tau level screen ( cut value CSF amyloid beta 142 CSF ptau and/or total tau base value establish Clinical Neurochemistry Lab , Sahlgrenska University Hospital , Mölndal , Sweden specify separate lab manual ) 2 ) positive 18Fflutematol amyloid positron emission tomography ( PET ) amyloid scan screening ( optional depend site 's PET capability ) Patients must body mass index ( BMI=weight/height² ) 18 35 kg/m2 , inclusive , screen Women must postmenopausal , permanently sterilize otherwise incapable pregnancy Must adhere require contraception 3 month study Patients must otherwise healthy age group medically stable without medication Patients must able compliant selfadministration medication Patients must able swallow drug whole Patient evidence brain disease , Alzheimer 's Disease ( AD ) , abnormality ( e.g . folic acid/Vitamin B12 deficiency ) could explain cognitive deficit ( include , limited vascular encephalopathy stroke , image cerebral MRI Major Depression , define DSMIV criterion ) Patient diagnose dementia due AD , due disease , AD contribution disorder ( mixed dementia ) Patient evidence familial autosomal dominant AD Patient history substance alcohol abuse Relevant history lower back pain scoliosis and/or major ( lumbar ) back surgery Patient allergic local anesthetic and/or iodine chlorhexidine Patient take aspirin ( even low dose ) within 5 day prior lumbar puncture ( screen Day 1 ) Patient take Low Molecular Weight Heparin ( LMWH ) within 12 hour prior lumbar puncture ( screen Day 1 ) Patient take anticoagulant treatment ( e.g . warfarin ; besides LMWH describe ) within 1 week prior lumbar puncture ( screen Day 1 )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Alzheimer Disease</keyword>
	<keyword>Prodromal Alzheimer Disease</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Proof Mechanism</keyword>
	<keyword>JNJ-54861911</keyword>
</DOC>